AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference

Rhea-AI Summary

AtriCure, Inc. (Nasdaq: ATRC) announced the release of its fourth quarter and full year 2023 financial results on February 15, 2024. The company will host an audio webcast to discuss the results and will also participate in investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, February 15, 2024, to discuss its fourth quarter and full year 2023 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.

AtriCure’s management is also scheduled to host investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024, in Snowbird, Utah.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240125185811/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com



Marissa Bych

Gilmartin Group

Investor Relations

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When will AtriCure release its fourth quarter and full year 2023 financial results?

AtriCure will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.

What is the ticker symbol for AtriCure?

The ticker symbol for AtriCure is ATRC.

Where can I listen to the audio webcast to discuss the financial results?

The audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.

When and where will AtriCure participate in investor meetings?

AtriCure's management is scheduled to host investor meetings at the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024, in Snowbird, Utah.